Phathom Pharmaceuticals Inc. (PHAT)
$10.69
$-0.19
(-1.75%)
As on 22-Jun-2026 16:00EDT
Market cap
$868 Mln
Revenue (TTM)
$205 Mln
P/E Ratio
--
P/B Ratio
25.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-34.9 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2.2
-
Debt to Equity
-0.5
-
Book Value
$--
-
EPS
$-2.1
-
Face value
--
-
Shares outstanding
79,755,953
6 Years Aggregate
CFO
$-539.95 Mln
EBITDA
$-747.10 Mln
Net Profit
$-917.04 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
| -35.6 | -7.7 | -4.6 | 2.6 | -5.8 | -21.2 | -- |
|
BSE Sensex
| -9.0 | 2.5 | 3.4 | -6.4 | 6.7 | 8.0 | 11.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
| 104.3 | -11.0 | -18.6 | -43.0 | -40.8 | 6.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
10.7 | 867.7 | 204.9 | -157.3 | -44.6 | -- | -- | 25.4 |
| 286.4 | 37,128.5 | 4,286.9 | 577.2 | 20.3 | 88.2 | 69.9 | 34.5 | |
| 82.0 | 11,524.9 | 622.0 | -300.9 | -25.7 | -61.1 | -- | 18.7 | |
| 51.4 | 13,047.8 | 2,375.5 | 833.4 | 41.5 | 40.7 | 17.2 | 6.7 | |
| 167.8 | 28,000.8 | 16,632.0 | 1,385.0 | 14.1 | 22.3 | 20.9 | 4.5 | |
| 512.9 | 11,660.4 | 1,132.5 | -309.4 | -25.0 | -52.9 | -- | 21.4 | |
| 455.7 | 13,143.2 | 2,678.3 | 460.4 | 21.3 | 103.2 | 29 | 22.0 | |
| 612.5 | 63,945.5 | 14,919.6 | 4,423.4 | 34.9 | 14.2 | 14.9 | 2.0 | |
| 538.3 | 22,776.5 | 3,169.8 | 1,287.4 | 51.3 | 20.6 | 19.8 | 3.9 | |
| 466.8 | 114,626.1 | 12,255.1 | 4,338.3 | 42.2 | 23.7 | 26.8 | 5.9 |
Shareholding Pattern
View DetailsAbout Phathom Pharmaceuticals (PHAT)
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment... of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. Read more
-
President, CEO & Director
Ms. Terrie J. Curran
-
President, CEO & Director
Ms. Terrie J. Curran
-
Headquarters
Florham Park, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Phathom Pharmaceuticals (PHAT)
What is the current share price of Phathom Pharmaceuticals Inc (PHAT) Today?
The share price of Phathom Pharmaceuticals Inc (PHAT) is $10.69 (NASDAQ) as of 22-Jun-2026 16:00 EDT. Phathom Pharmaceuticals Inc (PHAT) has given a return of -5.83% in the last 3 years.
What is the current PB & PE ratio of Phathom Pharmaceuticals Inc (PHAT)?
Since, TTM earnings of Phathom Pharmaceuticals Inc (PHAT) is negative, P/E ratio is not available.
The P/B ratio of Phathom Pharmaceuticals Inc (PHAT) is 25.37 times as on 18-Jun-2026, a 490 premium to its peers’ median range of 4.30 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-5.47
|
-2.76
|
|
2024
|
-1.53
|
-2.02
|
|
2023
|
-2.31
|
-6.40
|
|
2022
|
-2.21
|
-5.85
|
|
2021
|
-5.06
|
10.09
|
What is the 52 Week High and Low of Phathom Pharmaceuticals Inc (PHAT)?
The 52-week high and low of Phathom Pharmaceuticals Inc (PHAT) are Rs 18.31 and Rs 7.61 as of 23-Jun-2026.
What is the market cap of Phathom Pharmaceuticals Inc (PHAT)?
Phathom Pharmaceuticals Inc (PHAT) has a market capitalisation of $ 868 Mln as on 18-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Phathom Pharmaceuticals Inc (PHAT)?
Before investing in Phathom Pharmaceuticals Inc (PHAT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.